20,000 Shares in CareDx Inc (CDNA) Purchased by Ardsley Advisory Partners
Ardsley Advisory Partners acquired a new position in CareDx Inc (NASDAQ:CDNA) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 20,000 shares of the company’s stock, valued at approximately $147,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. FNY Partners Fund LP bought a new stake in shares of CareDx in the 4th quarter worth $102,000. Two Sigma Advisers LP bought a new stake in shares of CareDx in the 4th quarter worth $105,000. Wells Fargo & Company MN raised its stake in shares of CareDx by 1,360.6% in the 4th quarter. Wells Fargo & Company MN now owns 16,636 shares of the company’s stock worth $122,000 after buying an additional 15,497 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of CareDx in the 4th quarter worth $130,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of CareDx in the 4th quarter worth $134,000. 52.35% of the stock is currently owned by institutional investors.
A number of analysts have recently commented on CDNA shares. Zacks Investment Research downgraded CareDx from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. HC Wainwright initiated coverage on CareDx in a research report on Monday, November 27th. They set a “buy” rating and a $12.00 target price on the stock. Finally, ValuEngine lowered CareDx from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. CareDx presently has a consensus rating of “Buy” and an average target price of $8.65.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx Inc (NASDAQ:CDNA).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.